New drug may boost immunotherapy completion in lung cancer
NCT ID NCT06139419
First seen Nov 17, 2025 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tests whether thymosin alpha-1, an immune-boosting drug, helps people with advanced lung cancer complete a full year of immunotherapy after standard chemoradiation. About 114 participants will be randomly assigned to receive thymosin alpha-1 or not. The goal is to see if it improves survival and reduces side effects like pneumonia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun yat-sen university cancer center
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.